ArticleGastro hep advances2026
Quality of Life in Patients With Primary Sclerosing Cholangitis.
Article in Gastro hep advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: Primary sclerosing cholangitis (PSC) is an autoimmune chronic cholestatic liver disease causing inflammation, fibrosis, and increased risk of cholangitis, cirrhosis, and hepatobiliary cancers. How PSC affects patient-reported quality of life (QoL) is sparsely studied. We aimed to investigate the impact of PSC on QoL. Methods: This cross-sectional study included 101 patients with PSC. We investigated QoL using the PSC-specific PSC patient-reported outcome (PRO) instrument, the generic health-related QoL questionnaire EQ-5D-5L, and the fatigue visual analog scale (VAS) score. We also investigated associations between QoL and noninvasive inflammation and fibrosis measures; the macrophage marker soluble (s)CD163, fibrosis-4 score, and transient elastography. Results: The median age was 45 years, 65% were males, 10% had PSC with autoimmune hepatitis overlap disease, and 92% had inflammatory bowel disease. Eighty-five patients completed all QoL questionnaires and reported high QoL across all PSC PRO instrument items and EQ-5D-5L. sCD163 correlated modestly with PSC PRO total score (rho = 0.28) and fatigue VAS score (rho = 0.26) but not EQ-5D-5L. Patients with any previous episode of cholangitis reported lower QoL than cholangitis-naive patients on the PSC PRO score (21 vs 15, Conclusion: In this cohort, patients with PSC reported high QoL. The PSC PRO score correlated with sCD163 and was sensitive to cholangitis episodes, validating the instrument as a true PSC-specific QoL tool.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.